Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026032830?dgcid=rss_sd_all
Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026032830?dgcid=rss_sd_all
“Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article40962,
title = {Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026032830?dgcid=rss_sd_all}
}